Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics
- PMID: 40694275
- DOI: 10.1007/s12325-025-03287-4
Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics
Abstract
Introduction: Bleeding-related hospitalizations represent a major burden for patients and the US healthcare system. Anticoagulant therapies pose a greater risk for bleeding, especially among the older Medicare population. Direct oral anticoagulants (DOACs) have become the most common type of oral anticoagulant used in Medicare due to their clinical advantages. This descriptive study examines the burden of bleeding-related hospitalizations among DOAC users and nonusers (with no evidence of anticoagulant or antiplatelet use) in Medicare fee-for-service (FFS).
Methods: This was an observational retrospective cohort study of bleeding-related hospitalizations in Medicare FFS using the 2020-2022 Medicare 100% Research Identifiable Files. We used 2020-2021 pharmacy claims to classify beneficiaries into DOAC user and nonuser cohorts and 2021-2022 healthcare administrative claims to identify demographics, bleeding-related hospitalization characteristics, and outcomes.
Results: Of 18.4 million Medicare FFS beneficiaries who met the study's enrollment requirements, 9.3% were assigned to the DOAC user cohort, 81.5% were assigned to the nonuser cohort, and 9.1% were excluded (non-DOAC anticoagulant-only or prescription antiplatelet-only users). The bleeding-related hospitalization rate was four times higher in the DOAC user cohort compared to the nonuser cohort (27.5 and 6.7 per 1000 beneficiaries, respectively). Gastrointestinal bleeding was the most common bleed type leading to hospitalization in both DOAC user and nonuser cohorts (64.6% and 55.4%, respectively), followed by intracerebral hemorrhage (21.3% and 34.5%, respectively), and other types of bleeding (14.2% and 10.1%, respectively). Characteristics and outcomes were similar between cohorts, with variation largely related to bleeding type.
Conclusion: This study demonstrated variations in use of DOACs and characteristics of bleeding-related hospitalizations and identified higher rates of bleeding-related hospitalizations among DOAC users compared to nonusers. Hospitalization characteristics and outcomes differed by bleeding type. These findings highlight the Medicare FFS burden of bleeding-related hospitalizations and opportunities for the improved detection and management of bleeding, particularly among DOAC users.
Keywords: Administrative claims; Bleeding; DOAC; Demographics; Direct oral anticoagulant; Hospitalization; Medicare; Prevalence; Retrospective analysis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of Interest: Carol Bazell, Maggie Alston, Stephanie Leary, and Winston Fopalan are employees of Milliman Inc. and received consulting fees from AstraZeneca. Latha Ganti is a consultant for AstraZeneca. Raymond Chang and H Andrew Wilsey are employees of AstraZeneca Pharmaceuticals LP and own stock in AstraZeneca. Christopher Baugh is a paid speaker for Roche Diagnostics; participated in Roche Advisory Boards; is an advisor to Lucia Health Guidelines, Quai, and Vera Health; serves on advisory boards for Pfizer, Salix Pharmaceuticals, and AstraZeneca; and has received research funding support from Abbott Laboratories, Roche Diagnostics, and Sanofi. AstraZeneca Pharmaceuticals LP produces and markets ANDEXXA (coagulation factor Xa [recombinant], inactivated-zhzo), a drug used for the reversal of anticoagulation in patients treated with apixaban and rivaroxaban. The authors report no other conflicts of interest in this work. Ethical Approval: This manuscript is based on previously collected non-identifiable healthcare administrative claims data and does not contain any new studies with human participants or animals performed by any of the authors. All uses of data in this manuscript fall under Milliman Inc.’s existing data use agreements for the data sources.
Similar articles
-
Elective THA for Indications Other Than Osteoarthritis Is Associated With Increased Cost and Resource Use: A Medicare Database Study of 135,194 Claims.Clin Orthop Relat Res. 2024 Jul 1;482(7):1159-1170. doi: 10.1097/CORR.0000000000002922. Epub 2023 Nov 24. Clin Orthop Relat Res. 2024. PMID: 38011034 Free PMC article.
-
Use of Multiplex Molecular Panels to Diagnose Urinary Tract Infection in Older Adults.JAMA Netw Open. 2024 Nov 4;7(11):e2446842. doi: 10.1001/jamanetworkopen.2024.46842. JAMA Netw Open. 2024. PMID: 39589743 Free PMC article.
-
Quality of Hospices Used by Medicare Advantage and Traditional Fee-for-Service Beneficiaries.JAMA Netw Open. 2024 Dec 2;7(12):e2451227. doi: 10.1001/jamanetworkopen.2024.51227. JAMA Netw Open. 2024. PMID: 39680405 Free PMC article.
-
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.Cochrane Database Syst Rev. 2016 Mar 30;3(3):CD004179. doi: 10.1002/14651858.CD004179.pub2. Cochrane Database Syst Rev. 2016. PMID: 27027384 Free PMC article.
-
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2. Cochrane Database Syst Rev. 2017. PMID: 29105079 Free PMC article.
References
-
- Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. Gastroenterology. 2022;162(2):621–44. - PubMed
-
- Bako AT, Pan A, Potter T, et al. Contemporary trends in the nationwide incidence of primary intracerebral hemorrhage. Stroke. 2022;53(3):e70–4. - PubMed
-
- Chan NC, Weitz JI. Antithrombotic agents. Circ Res. 2019;124(3):426–36. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous